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Abstract 
Introduction: Visceral leishmaniasis (VL) and malaria co-infection is common in VL 
endemic areas. The occurrence of this two parasitic disease simultaneously occurred on 
the same host at a time resulted in sever clinical presentation and poor or delayed 
prognosis and finally may lead to death. It is reported that there is co-infection of these 
two disease in all endemic regions of the world. 
Objective: The objective of this study was to identify factors associated with mortality 
among visceral leishmaniasis and malaria co-infected patients from 2010-2016 in 
northwest Ethiopia. 
Methods: A retrospective study was carried out. Data were extracted from routinely 
collected patient’s records by Medicines Sans Frontiers Holland between 2010 and 2016 
in northwest Ethiopia. A total of 123 VL-malaria co-infected and 387 VL-Mono infected 
randomly selected patient’s record were reviewed. Data were entered into EPI INFO 7, 
analyzed using SPSS. Both bivariable and multivariable logistic regression analysis was 
done. A p-value less than 0.05 was taken as statistical significant with 95% confidence 
level.   
Results: A total of 510 VL patients’ medical records reviewed, 123 VL-malaria co-
infected and 387 VL mono infected patients were studied. Among them 25 deaths 
recorded (10 from exposed group 15 from none exposed group), with case fatality rate of 
8.1% and 3.8% respectively. Malnutrition (AOR=69.11: 95%CI: 3.39, 1406) and 
splenomegaly (AOR: 0.16, 95%CI 0.04, 0.86) were associated with the mortality. 
Conclusions and Recommendation: Malnutrition and splenomegaly was associated 
with the VL-malaria coinfection associated deaths. Health professionals should be good 
enough when doing physical examination, balanced and adequate nutrition for co-
infected patients is very mandatory. 
Keywords: Co-infection, VL-malaria, retrospective, Northwest Ethiopia. 
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1. Introduction 
1.1. Problem Statement 
The geographic overlap in the occurrence of leishmaniasis and malaria was reported in 
endemic areas.[1, 2] Leishmaniasis and malaria cases are prevalent in South Asia, Latin 
America [3-5]. Visceral Leishmaniasis (VL) together with malaria is common in east 
African countries with prevalence of 20%in Uganda, 26.2% in Sudan.[6, 7].6% in India 
and <1% in Bangladesh [8]. 
The co-infection is presented with from the potential diagnostic delay to significant clinical 
implications and increased level of disease-related morbidity and mortality [7]. Co-
infected patients presented at hospital with deteriorated clinical pictures and side effects 
of the drugs also challenging as compared to mono-parasitic infections[9].  
World Health Organization (WHO) estimates that from about 900,000 to 1.3 million new 
leishmaniasis cases, 200,000 to 400,000 visceral leishmaniasis and 700,000 to 1.2 million 
cutaneous leishmaniasis case loads annually in the world. Among the cases 90% were 
found in six countries; India, Bangladesh, South Sudan, Sudan, Brazil, and Ethiopia [10]. 
The disease burden is very high in east Africa which accounts 29,400 to 56, 600 cases 
annually. Sudan shares nearly half of east African leishmaniasis cases estimated 15,000-
20,000 yearly [11]. Visceral leishmaniasis is one of the re-emerging public health problem 
in Ethiopia after index case known the first time in 1942 in the southern Ethiopia [12]. 
Currently estimated 3700-7400 new leishmaniasis cases and 3.2 million people at risk 
annually. The northwestern lowland of Ethiopia have more than 60% cases clustered. In 
this region poor, seasonal young migrant workers are more affected [13, 14].Malaria is 
the leading prevalent and killer parasitic disease, caused by four main plasmodium 
species namely Plasmodium falciparum, Plasmodium vivax, plasmodium malarae, and 
plasmodium ovale. Globally half billion people at risk with 289 million at high risk in 2015 
and 212 million cases per year and 429 000 deaths. Among all deaths 90% occur in WHO 
African region [15]. 
However the basic information lacks in Ethiopia about the co-occurrence and outcomes 
of malaria and Visceral leishmaniasis. This study were identified factors associated with 
mortality among VL-malaria co-infected patients. The study area is highly endemic for 
malaria and more than 60% of the country’s VL burden.  
  
 
2 
 
1.2. Literature Review 
Malaria is commonly occurred in VL patients in endemic areas [3]. There is some 
evidences of VL-malaria co-infection all over the world. VL-Malaria Co-infection is higher 
in Africa. 26% in Sudan and nearly 20% in Uganda. From VL-Malaria co-diagnosed 
patients in Sudan 3.5 % of whom died, while lower fatality rate among controls, 2.8% [6, 
7]. No difference in case fatality among cases and controls, 3.5% & 2.8% and 2.7% & 
3.1% in Sudan and Uganda respectively. 
Study done in Sudan showed that co-infected patients treated with arthemeter and 
quinine to treat malaria were 13 to 15 fold mortality risk than treated with artesunate + 
sulfadoxine-pyrimethamine (SP). Of those died patient’s higher density of leishmaniasis 
parasite in their lymph nodes and bone marrow was found to be increasing the mortality 
risk [7]. There also seen elevated serum Immuno Globulin E (IgE) response in malaria 
patients irrespective of helminth infection and its correlation with high malaria parasite 
load and helminth egg density. Malaria infection is also a strong driver of IgE production 
as compared to helminthes [16]. In Malawi children diagnosed with cerebral malaria and 
HIV coinfection more (23%) case fatality rate than 17% none HIV infection children. 
Cerebral malaria is a major contributor to malaria deaths [17]. Plasmodium yoelii Malaria 
and cutaneous Leishmaniasis (Leishmaniasis .amazonesis species) co-infection  among 
trial mice in Brazil was found to be 30% death from cases, while 100% survival among 
the control groups [3]. 
Visceral leishmaniasis, and malaria are well known health problems in the lowlands of 
Ethiopia, currently these diseases spreading to the adjacent semi-lowland and highland 
areas. The 2005-2007 outbreaks of VL in south Gondar zone, Adiszemen area is the 
typical example, which leads hundreds for death [18].  
VL is most sever forms of leishmaniasis which affects the reticuloendothelial systems, in 
low socioeconomic portion of the population, In Bangladesh, about 33.3% (4/12) 
confirmed deaths didn’t get leishmaniasis treatment[19].  
Globally over 40 million people displaced in 2015 as a result of natural disaster, war and 
violence related to religious and ethnic conflicts. Internal displacement in sub Saharan 
Africa leads people to potential health problems, like malaria and leishmaniasis 
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[20].Studies showed that cross border movement is highly associated with malaria 
infection [21]. Clinical malaria also observed in people with history of travel to malaria 
endemic areas [22]. Migration of daily laborers to and from endemic areas, HIV, 
Malnutrition, climate and environment change affects VL disease distribution and 
progression rate[23]. 
Major agriculture projects and mechanized farms, ongoing mega projects have main 
benefits in economic advancement, but the control and prevention measures of infectious 
tropical diseases is poor[24]. 
Abdurafi is a place which many young migrant workers travel every year for sesame and 
cotton harvesting. Evidences in northwest Ethiopia showed that the highest prevalence 
of VL cases was from Autumn (September to November) followed by Winter (December 
to February) with lower prevalence in spring (march to May) [13]. Similar study showed 
that November to May was peak seasons for the VL-Malaria co-infection because malaria 
occurs during or immediately after rainy season and VL more common in dry season. So 
health professional need alertness in diagnosing both diseases in endemic areas, 
presenting with prolonged fever, hepatosplenomegaly and lymphadenopathy all over the 
year  including the ability to diagnose the atypical presentation of leishmaniasis  to prevent 
delay[24]. 
Leishmaniasis- malaria co-infection resulted in leishmaniasis driven effects may change 
the immune response regulated by these disease, as a result there also be delayed 
prognosis[25]. Emaciation, jaundice & anemia [7]. Anorexia, malaise, vomiting, more 
severe symptoms and young age males was most significantly affected group which have 
association for co-infection [6, 26]. Study suggest that patients aged between 12 and 18 
months, with platelet counts below 85,000/mm3, and respiratory abnormalities at 
admission should be considered potentially severe [27]. 
There was multiple positive correlation in pro-inflammatory vs. type-1 cytokines and pro-
inflammatory and type 2- cytokines exhibited in Sudanese patients.[28] Risk of death is 
high in VL patients associated with weakness, old age (> 60), bleeding, and jaundice [29]. 
Previous exposure to plasmodium infection was found to be a predictor for the 
manifestation of malnutrition in under-five children [30]. Visceral leishmaniasis is 
misdiagnosed or mimics with many febrile illnesses like, chronic malaria, hyper reactive 
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malarial syndrome (HMS), shistosomiasis, typhoid fever miliary tuberculosis and 
brucellosis[13].  
Occurrence of the co-infection alters the natural outcome and progression of diseases 
due to modulation of immune response [5]. In patients co-infected by HIV, malaria and 
leishmaniasis faced significant complications on the treatment of those diseases, in that 
protozoan parasites enhance the fast replication of the HIV leading to AIDS stage and on 
the other hand HIV changes the pathogenesis of malaria and leishmaniasis causing 
parasites[23, 31]. In the same way VL is the commonest opportunistic infection in HIV 
patients in VL endemic areas. Eastern Africa has the largest VL-HIV caseload in the world 
[32]. 
The overall case-fatality rate in patients treated by AmBisome was 6.6% increased by 
half (3.3%) from non HIV infected patients related with poor treatment outcome were HIV 
infection, bleeding and a previous VL episode [33]. Similarly patients with visceral 
leishmaniasis and HIV coinfection who treated by SSG exhibited 43.9% cure rate. 31.6% 
and 14% parasitological treatment failure and case fatality rate respectively.[34]Death, 
treatment failure was found to be high specially in severely ill (unable to walk) and HIV-
VL co-infected patients in northwest Ethiopia[35]. pancreatitis is the common side effect 
of SSG [36]. Sodium stibogluconate (SSG) was found to be 75% effective in Northwest 
Ethiopia for longer duration. VL recurrence mostly occurred in Metema, West Armachiho 
and Humera areas which is common VL and malaria focus, bordering Sudan and 
Eritrea.[37]. 
Visceral leishmaniasis patients co-diagnosed with hepatitis B or C have significantly 
increased levels of AST, ALT. also decreased level of platelet and albumin level[38]. 
Sever malaria is a major cause of mortality in children [39].HIV and malaria infected 
hospitalized children in Tanzania exhibited delayed malaria parasite 
clearance[40].Atypical presentation of VL is high when there is co-occurred with other 
infections and there is under diagnosis of VL, leading patients to leishmaniasis associated 
morbidity and mortality [41]. 
Leishmaniasis is the second parasitic killer next to malaria and the fifth opportunistic 
disease in the world [37]. Visceral leishmaniasis is a neglected disease caused by 
protozoan parasites. It occurs worldwide including Africa, Asia, Europe and Latin 
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America[2]. If there is no early diagnosis and treatment leishmaniasis is highly fatal 
disease. But with proper treatment it is curable [13]. VL treatment drug side effects 
negatively affects the quality of life of patients living with HIV/AIDS in Northern Ethiopia 
[42].  
However, VL-Malaria co-infection researches are limited all over the VL and malaria 
endemic focus areas including Ethiopia. There is scarcity of information and there were 
expected mortality of these co-infection. So this study were assessed the factors 
associated with mortality among VL-Malaria co-infected patients in northwest Ethiopia.  
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Conceptual Framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Conceptual framework factors associated with mortality among VL-malaria co-
infected patients. Developed after different literatures reviewed [3-7] 
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1.3. Justification 
 
Visceral leishmaniasis and malaria is commonly occurred in VL endemic areas. As 
studies showed that there is occurrence of the coinfection in the study area.  Despite the 
fact that some studies done to address this area of concern. But the factors associated 
with mortality is not investigated in endemic areas of Ethiopia. 
If there is misdiagnosis and delay Leishmaniasis is more than 95% fatal disease if 
untreated early. Malaria also have significantly fatal, in 2015 there was 429,000 deaths 
from malaria globally, and WHO African region shares 92% of it, and most deaths were 
due to Falciparum malaria which is very common in the study area. If it is co-occurred at 
a time the severity and response to treatment may be very challenging. 
Studies conducted previously were not much enough to describe about factors associated 
with mortality among co-infected patients and it was done in different population, in 
Sudan, Uganda, and Malaysia.  
This study was investigated the factors associated with mortality among VL-Malaria co-
infection in northwest Ethiopia. The finding may also serve as an important tool for any 
possible interventions aimed at improving good clinical and treatment outcomes of co-
infected patients. 
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2. Objective 
Assessment of factors associated with mortality among Visceral Leishmaniasis patients 
co-infected with malaria who were admitted in MSF-Holland Abdurafi kala-azar, HIV/AIDS 
and malnutrition project from 2010 to 2016, Northwest Ethiopia. 
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3. Methods and Materials 
3.1. Study design 
Retrospective cohort study was carried out from patient records. Visceral leishmaniasis 
and malaria co-infected and VL mono-infected patients were included in this study. 
Patients with laboratory confirmed diagnosis of both VL and Malaria at hospital admission 
or during hospital stay was taken as exposed, whereas, laboratory confirmed VL and 
having laboratory confirmed negative malaria laboratory test result were none exposed.  
3.2. Study area and period 
The study area is located in northwest, Ethiopia with Latitude 13°43'60.0"N (13.7333300°) 
and Longitude 36°27'00.0"E (36.4500000°) in Amhara region, Mirab Armachiho district, 
bordered south by Metema, west by Sudan, north by the western Tigray, northeast by 
Tegede district, and on the east by Tach Armachiho. Abdurafi is one of the town in west 
Armachiho district found north, 27km, 250km and 995km far from Abrhajira (center of the 
district), Gonder and Addis Abeba respectively. Abdurafi has one Government health 
center, one nongovernmental humanitarian medical organization (MSF-Holland) kala-
azar, and malnutrition and HIV treatment center (Hospital) about 15 private clinics. 
Every year as many as 300,000-500,000 daily laborers migrate for commercial cotton and 
sesame farms, the harvesting season in the farming area of Abdurafi, near the Sudanese 
and Eritrean border. Their work and living conditions are extremely basic and leave them 
vulnerable to fatal diseases like VL. 
Medecins Sans Frontiers-Holland is giving voluntary medical, humanitarian service by 
giving free treatment for VL, Malnutrition, HIV/AIDS and other emergencies in 
collaboration with Ministry of Health since 1997 in northwest Ethiopia. Outreach services 
on VL and malnutrition control & prevention and many randomized controlled trials in 
collaboration with (Drugs for Neglected Disease Initiative (DNDi) are the projects main 
tasks in the area. This hospital has 100 beds and five wards for admission and treatment 
of Leishmaniasis, leishmaniasis-HIV co-infection, Leishmaniasis- complicated malaria, 
Tuberculosis and complicated sever acute malnutrition patients.  
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3.3. Source Population 
The source population of this study was patients who were admitted in MSF-H kala-azar, 
HIV/AIDS and Malnutrition project for diagnosis and treatment from January 1, 2010 to 
December 31, 2016G.C.Total patients admitted and treated from 2010-2016 were10458, 
2383 of them were leishmaniasis patients. 
3.4. Study Population 
Subjects were all laboratory confirmed visceral leishmaniasis and/or malaria patients. 
Who were admitted in abdurafi MSF-H VL, HIV/AIDS and Malnutrition project between 
January 1, 2010 and December 31, 2016. 
3.5. Inclusion Criteria 
All VL patients who were confirmed by laboratory investigations (rK39 and/or DAT for 
primary visceral leishmaniasis b 
ut Bone marrow, spleen aspiration or lymph node aspiration for relapse and/or if failed 
serologic test but fulfilling the WHO VL case definition. Incomplete data that was expected 
to be meaningful for analysis included in the study, but still if there is difficulty to give 
meaning the data were excluded because of incompleteness.  
3.6. Exclusion Criteria 
Patients those who have more than 40% incomplete data in the diagnosis, treatment and 
socio demographic characteristics were excluded from this study. Patients those who 
have third morbidity HIV and TB was excluded from the study to avoid confounding effect 
on the outcome variable.  
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3.7. Sample Size and Sampling Procedure 
The sample size was determined by using from previous similar study done in Sudan and 
that were give the highest sample size. % of outcome in unexposed group= 20%, outcome 
in exposed group: 33.3%, Odds ratio=2, Confidence level=95%, Power= 80% and Ratio  
unexposed to exposed 3:1 then using EPI-Info version 7 population survey unmatched 
cohort formula, given that 480, with the addition of 5% attrition rate it was 504. Finally 
data was collected from 510 study subjects (123 exposed and 387 none exposed groups). 
Simple random sampling method was used. Samples were selected using Openepi, 
random number generator. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 2. Schematic presentation of sampling procedure. 
 
2010 2011 2012 2013 2014 2015 2016 
52:398 80:337 76:323 72:282 104:501 63:300 63:239 
13:39 20:60 17:58 18:58 25:78 15:48 15:46 
Estimated VL-malaria co-infected and VL-mono 
infected=510 
 
Proportional allocation samples to each 
year using simple random sampling 
(computer random number generator) 
was used 
Total exposed to none exposed n= 
387 to 123= 510)   (3:1 ratio) 
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3.8. Study variables 
3.8.1. Outcome variable 
                 Mortality  
3.8.2. Explanatory variables 
A. Socio-demographic variables 
Age, sex, residence 
B. Clinical signs and symptoms 
Anorexia, Anemia, malaise, vomiting, diarrhea, parasite load, spleen size, cough, CBC profile, 
Pancreatitis, Jaundice, Poor appetite 
C. Malaria and VL treatment related factors 
Type of anti-malaria treatment, time course of treatment, drug adverse event, dose of treatment, 
Two drug combination, three drug combination, treatment shift 
D. Nutritional factor 
Severe malnutrition  
Moderate Malnutrition 
E. Season related factors 
Dry season, Rainy season 
3.9. Data collection 
Data was collected on the routine patient care registry by MSF-Abdurafi Kala-azar, 
HIV/AIDS and Malnutrition project. After selecting the sample data was taken from the 
patient charts as well as Medecines Sans Frontiers Operational Center Amsterdam 
databases (MSF-OCA) by using readymade data extraction sheet after ethical clearance 
from MSF-OCA and University of Gondar institution review board obtained.  Patients 
diagnosed by RDT and/or microscopically positive malaria test and serologically and/or 
parasitological tested positive. VL-mono infected group was selected randomly from VL- 
none malaria patients diagnosed and treated in the study period. Sociodemographic 
details, clinical signs and symptoms, nutritional status, treatment season, laboratory test 
results, medical treatments and its outcomes was extracted.  
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3.10. Data Quality Assurance 
Two BSC nurses for data collection and one health officer for supervision was recruited 
for data extraction. Training about data extraction procedure was briefly communicated. 
The supervisor and the data extractors were checked and clean the data after end of 
each data extraction date. 
3.11. Data processing and analysis 
After data collection extraction sheets were collected from data collectors, coded and 
cleaned for its completeness. Then data entered to EPI info version 7 and imported to 
SPSS version 20 statistical software packages by principal investigator.Counts, tables 
were used for the descriptive summary. Binary logistics regression model were fitted. A 
p-value of <0.05% was used to say significantly associated between the explanatory and 
outcome variables with 95% confidence level. 
An association between the dependent and independent variables was assessed by both 
binary and multiple logistic regressions and strength of its association was presented 
using odds ratio with 95% confidence level. Factors statistically significant at 0.2 in the 
bivariable logistic regression model remained in multivariate model to control the effect of 
confounders. 
3.12. Operational Definition 
Exposed; Positive parasitological demonstrated parasites in a lymph node, spleen, or 
bone marrow aspirates or Positive direct DAT (Direct Agglutination Test) and/or positive 
rk39-based rapid test for VL and RDT and/or microscopically confirmed malaria parasite 
from blood smear. 
None-exposed: Visceral leishmaniasis mono infected group were laboratory 
(serologically or parasitological) confirmed VL but malaria RDT or thick or thin smear 
microscopic confirmed negative test result. 
Anemia; Anemia is defined as the hemoglobin level less than the reference level 
(<10g/dl) in tropical settings. None - mild (Hgb ≥7.3 g/dl), Moderate (Hgb 5.3-7.2 g/dl), 
Severe (Hgb<5.3 g/dl). (WHO) 
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Rainy season: The rainy season in Ethiopia covers from June to September. 
Dry season: October to May is dry season relatively in Ethiopia climate condition 
Co-infection: Coinfection may result when hosts are independently infected by different 
parasites at the same time or when interactions among parasites species facilitate co-
occurrence. 
Cured; A definitive cure is the absence of visceral Leishmaniasis signs and symptoms 
and a negative test of cure 6 months after initial cure, and absence of malaria sign and 
symptoms.(definitive cure). Free of sign and symptom after end of VL treatment and 
Malaria confirmed by laboratory test or clinical confirmation by Doctor or Health officer. 
Death/Mortality: patient dead due to or its complications of either by malaria and/or VL 
which was confirmed by Doctor or Health Officer during hospitalization period and having 
death certificate. 
Resident: One who reside in a particular place permanently or for an extended period for 
equal to more than two years.  
Migrant worker: A person who moves to area in order to find employment in a particular 
seasonal or temporarily. (Less than two years in the area source: MSF-H working criteria). 
Splenomegaly: spleen enlarged below left costal margin considered to be have 
splenomegaly, most commonly the spleen is palpable by the second week of illness and, 
depending on the duration of illness, it becomes hugely enlarged([43] 
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4. Ethical Considerations 
 
Initially ethical approval and permission letter was obtained from Research Ethical 
Committee of    University of Gondar and from Medecins Sans Frontiers-Holland (MSF-
H) Ethical Review Board then formal letter got from University of Gondar (UoG) and email 
confirmation from MSF-H before the study. The study participant’s data were reviewed by 
trained health professionals kept confidentially, personal identifiers was masked and were 
not used for any other purpose other than this study. 
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5. Results 
5.1. Socio demographic characteristics 
A total of 510(123 VL-malaria co-infected (exposed) and 387 VL-None malaria (None-
exposed) patients were studied. A total of 2383 patient’s diagnosed and treated for VL 
hospitalized in Medicines Sans Frontiers Holland abdurafi Kala-azar, HIV and malnutrition 
project, northwest Ethiopia from January, 2010 to December, 2016. 
Total of twenty five deaths registered (10 from VL-malaria co-infected and 15 from non-
malaria VL co-infected) with case fatality rate of the coinfection was 8.1% versus 3.8% 
among unexposed group. 
Among the total patients 98.4 %( n= 121) were males from exposed and 98.4(n=381) 
from non-exposed).The mean age of 24.1 years (SD±7.9) for VL-malaria co-infected 
patients and 25.3(+7.8) for VL mono infected patients. More than half of the patients 
(54%) were within the age of 20-29 years. Amhara region residents were 87.3%through 
period of their illness before admission and more time live in the area, followed by (n=28, 
5.5%) from Tigray region and the rest (n=2, 0.2%) were came from Sudan.  
Among 510 included study participants 418 (78.4%) were diagnosed by serologic tests 
for VL were made by rK39 (DiaMed IT-Leish) (n=418, 78.4 %), DAT on (n=42, 8.2%) and 
Microscopic direct parasite observation (n=70 13.7%). From total aspirations spleen 
aspirates (n=52, 10%), Bone marrow aspirates (n=18, 3.5%). Malaria was confirmed by 
(n=274, 53.8%) by rapid diagnostic tests (RDT) microscopically with thin and thick blood 
film (n=236, 46.2%). Among exposed group 68% (n=85) species was P.falciparum 
resulted in cause to death of (n=6, 60%), followed by (n=2, 20%) P.vivax and (n=2, 20%) 
with P.falciparum and P.vivax mixed infections during admission or through time of 
hospitalization. Most patients (n=72, 58.5% and n=220, 56.8%) were hospitalized from 
June to September.  
Most (n=481, 94%) diagnosed as primary VL 23 of them died, 2 deaths recorded from 
relapses. From the total VL confirmed patients (n=123, 24.1%) were co-infected with 
malaria.  
 
  
 
17 
 
Table 1. Socio demographic and other variables frequency with its percentage, among abdurafi-
MSF-Holland Kala-azar, HIV/AIDS and Malnutrition project (2010-2016), northwest Ethiopia. 
 
 
 
 
Variables Categories VL-malaria co-
infected 
Non-Malaria VL 
   
Frequency 
 
% 
 
Frequency 
 
% 
Age in years 0-9 5/122 4.1 9/384 2.3 
10-19 23/122 18.7 66/384 17.1 
20-29 65/122 52.8  
210/384 
 
54.3 
>=30 29/122 23.6 99 25.6 
 
Gender 
Male 2/122 1.6 381/387 98.4 
Female 121/122 98.4 6/387 1.6 
 
Season on admission 
 
 
 
 
 
Dry season 
 
 
72/122 
 
58.5 
 
220/387 
 
56.8 
Wet Season 50/122 43.2 167/387 43.2 
 
Malnutrition 
 
BMI<18.5(MAM + SAM) 
 
 
36/123 
 
29.3 
195/385  
50.4 
BMI > 18.5 
 
87/123 70.7 190/385  
49.4 
Splenomegaly               
 
Yes  
105/120 
 
85.4 
 
302/386 
 
78 
No  
15/120 
 
12.2 
 
84/346 
 
21.7 
 
Anemia level(admission) 
(Sever, Moderate,, mild or 
No anemia) 
 
 
(Hemoglobin <11g/dl 
 
 
107/123 
 
 
87 
 
344/383 
 
88.9 
 
Hemoglobin >=11g/dl 
 
16/123 
 
13 
39/383 
 
 
11.1 
 
Residence status 
 
 
 
 
Migrant worker 
 
62/120 
 
50.4 
 
140/386 
 
36.2 
 
Resident 
 
58/120 
 
47.2 
 
246/386 
 
63.6 
 
Admission spleen 
size(BCM)  
 
 
 
0-3cm 
 
32/123 
 
26 
 
127/386 
 
32.8 
4-5 cm 
 
 
34/123 
 
27.6 
 
105/386 
27.1 
6+  
 
57/123 46.3 154/386 39.8 
 
VL type 
 
Primary VL 
110/121 89.4 371/386 96.1 
 
Relapse VL 
11/121 8.9 15/386         3.9 
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Table 2. VL-Malaria and VL none malaria patients showed clinical symptoms and death 
status, in abdurafi MSF-Kala-azar, HIV and malnutrition Hospital, Ethiopia (2010-2016).  
 
 
 
 
 
 
 
 
 
Majority 111 (90.2%) of the patients who live in Amhara region during time of admission 
were co-infected with VL and malaria, majority were in west Armachiho district (n=110, 
89.4%). Anemia (hemoglobin level <10.9 g/dl) was a very common condition in both 
groups (87% and 89.7%), exposed and non-exposed respectively. Average duration of 
hospital stay relatively high among VL-malaria co-infected group (33.9, SD=+22.4) as compared 
to VL mono-infected group (Mean=30.2 days, SD= +14.6).  
Bivariable and Multivariable logistic regression analysis 
Significant associations were found between death and variables Splenomegaly and 
malnutrition during admission (BMI<18.5) among the co-infected group by bivariate and 
multivariate logistic regression analysis. Other variable which show significant association 
with the outcome variable by bivariate analysis were hemoglobin level <11g/dl, Season 
on admission and residence status (being migrant worker). See table 3 
Malnutrition is the main risk factor which leads VL-malaria co-infected patients 69 times 
more likely to die than VL-mono infected patients (AOR. 69.11, 95% CI 3.39, 1406). 
Clinical signs and 
symptoms 
VL-Malaria None Malaria-VL  
 
Dead 
 
Not dead 
 
Dead 
 
Not dead 
Total 
Vomiting Yes 0 1 0 0 1 
No 0 112 15 372 499 
Headache Yes 1 2 0 0 3 
No 9 111 15 372 498 
Diarrhea Yes 1 0 0 0 1 
No 9 113 15 375 489 
Splenomegaly Yes 6 11 3 81 100 
No 4 99 12 290 405 
Joint pain Yes 0 3 0 1 4 
No 10 110 15 367 492 
Edema Yes 0 3 0 8 11 
No 10 110 0 364 484 
Sever 
Weakness 
Yes 3 34 2 46 85 
No 7 78 13 324 422 
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Patients those who had enlarged spleen below the left costal margin at the left upper 
quadrant (AOR=0.1: 95% CI 0.01, 0.86) were 90 times less likely to die in reference with 
no palpable spleen among the VL-malaria co-infected patients. But unlikely for patients 
with VL only. (AOR= 1.01, 95% CI 0.26 to 3.82). 
Most deaths recorded in wet season among co-infected group (8, 80%) but season on 
admission was not risk factor for mortality, (AOR=3.63, 95%CI: 0.49, 26.60). which means 
the co-infection had no difference with VL-mono-infected group (AOR= 1.14, 95% CI 0.39-
3.37) and (n=8, 53.3%)as compared to dry season. with the case-fatality rate of being co-
infected was 8.1%. Most Co-infected and none co-infected groups in the wet season 
(n=32, 64% and n=82, 49.7%) respectively was sever to moderate malnutrition with body 
mass index (BMI) of <18.5. No statistically significant difference on death among Sever, 
Moderate and mild malnutrition’s (BMI<16 <17 and <18.5 respectively). P.falciparum 
Malaria was the leading cause of death from malaria species among co-infected group.  
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Table 3.  Bivariable and Multivariable analysis of VL-malaria co-infected and VL-mono 
infected patients at Abdurafi MSF-Holland kala-azar, malnutrition and HIV/AIDS project, 
Ethiopia (2010-2016), Northwest, Ethiopia. 
 
1= reference, *: Showed the significant variable with p-value of less than 0.05, 95% CI 
 
 
 
 
 
 
Variables                       Exposed             Non-Exposed  
No
t 
de
ad 
De
ad 
COR (95% CI) 
 
AOR ( 95% CI) 
 
Not 
dead 
D
ea
d 
COR (95% CI) 
Crud 
AOR ( 95% CI) 
   Adjusted 
 
Residence           
Resident 52 6 1 1 233 13 1 1  
Migrant  
Worker 
59 3 0.44(0.10, 1.85) 0.73(0.11, 4.92) 138 2 0.26(0.05,1.16) 0.28(0.06, 1.29)  
Season          
Dry season  70 2 1 1 212 8 1 1  
Wet season 42 8 6.66(1.35,32.88) 3.63(0.49,26.60) 160 7 1.15(0.41,3.26) 1.14(0.39,3.26)  
BMI          
BMI>18.5 27 1 1 1 191 4 1 1  
BMI <18.5 86 9 28.6(3.47,236.6) 69.11(3.39,1406)* 179 11 2.93(0.91,9.38) 2.85(0.87,9.27)  
Hgb level          
>=11g/dl (No 
anemia) 
13 3 1  35 4 1   
<11 g/dl (mild to  
severe anemia) 
100 7 0.30(0.07,1.32) 0.07(0.005, 1.02) 333 11 0.28(0.08,0.95) 0.34(0.10,1.18)  
Splenomegaly          
No 11 4 1 1 81 3 1 1  
Yes 99 6 0.16(0.04, 0.68) 0.10(0.01,0.86)* 290 12 1.11(0.30,4.05) 1.01(0.26,0.86)  
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6. Discussion 
In this study the main findings were malnutrition BMI<18.5kg/m2 and absence of 
splenomegaly were risk factors for death. The co-infection from the co-infected group. 
Leishmania mostly affects low socioeconomic countries and where it often co-exists with 
chronic malnutrition. 
On the other hand malaria and leishmaniasis are the two most important public health 
problems in the world. Chronic malnutrition is one of the main risk factors for developing 
the disease. Leishmania is fatal protozoan disease if left untreated cause morbidity and 
mortality as a result of malnutrition by exposing the host to impairments of the disease 
defense mechanism [44]. 
Few studies have been published on VL-malaria coinfection, on the relationship between 
leishmaniasis progression and malnutrition and malaria coinfection. Most patients 
exhibited poor prognosis after admission with the presence of malnutrition it may worsen 
to a condition with sever diseases stage and death as evidenced by average length of 
hospitalization days of VL-Malaria co-infected patients were higher than the none-
exposed group. This is similar finding with a study done on VL in northern Ethiopia. [45] 
 P.falciparum were the major protozoan malaria causative agent among the total VL 
malaria co-infected patients. Previous studies had similar findings with this fact that was 
done on children past exposure of the plasmodium had significant impact on nutritional 
status of children [46]. 
In this study malnutrition had risk factor for death of 24% exposed group than none 
exposed group (AOR=69.11, 95% CI: 3.39-1406 and AOR=2.85 95 % CI 0.87, 9.27 
respectively).VL was found to be decreased level of the serum nutrients as a comparative 
study showed in Bangladesh on serum iron. In fact both parasites use red blood cells for 
their survival mechanism. Progressively leads to low iron deficiency anemia with low 
oxygen carrier hemoglobin as evidenced by this study most (87%) exposed and 89% non-
exposed group were anemic [47]. Body mass index measures the body’s fat accumulation 
as this study patients were severely wasted, Evidences showed that protein malnutrition 
is the most deleterious cause of malnutrition in developing countries. Also considered to 
be the first risk factor for the development of clinical visceral leishmaniasis (VL) and 
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favorable environment for the replication of the L.donovani species, Malnutrition 
(BMI<18.5) was identified as a risk factor for concomitant VL and malaria co-infection 
related deaths.   
Those patients who had palpable spleen below the costal margin were negatively 
correlated with the co-infection and death. This is in agreement with Erika van den 
Bogaart et al. from those who investigated the VL-malaria coinfection in the same study 
populations. Those who have no splenomegaly were more suffered from the co-infection 
this may be because of early arrival to health institutions may be due to the increased 
intensity of disease progression to seek health care earlier. This is in line with Erika van 
den Bogaart et.al on the similar study in Sudan and Uganda done among surveys on 
hospitalized patients [6, 7]. On the other hand there may be negligence or under care of 
patients by health care workers with no splenomegaly, since splenomegaly is one of the 
clinical case definition of VL. 
The in-hospital case-fatality rate was significantly higher (8.1% among exposed and 3.1 
none exposed). The case fatality rate among the co-infected group in this study was 
higher than the Sudanese and Ugandan patients (8.1% vs. 2.7%, 3.5% respectively). The 
difference may be resulted in the people are quite different genetically,  in this study 
almost half were migrant workers originated from highland areas and low immune for 
malaria and Leishmania infections, while the Sudanese patients were reported as 
residents in the area that may make them to develop partial immunity for this two parasitic 
diseases.    As a result the disease progression may be slower and low risk to death. May 
be the sample size and the method used may bring the difference in case fatality in this 
two studies. But the case fatality of this study was lower case fatality rate than co-infection 
trial mice in Brazil, 30% death from cases, while 100% survival among the control 
groups.[3] 
 
 
 
  
 
23 
 
Limitations of the study 
This study was used secondary data so that some important variables missed because 
of the incompleteness from patient records like some clinical variables jaundice, edema.  
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7. Conclusion 
 
Malnutrition is the most common risk factor for VL-malaria co-infections associated 
deaths. More than 90% of VL-malaria patients had malnutrition with BMI of <18.5kg/m2. 
Patients who had non palpable spleen size were higher probability of death among VL-
malaria co-infected than VL-mono infected patients.  
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Recommendations 
There should be VL and malaria preventive measures, treatment of visceral leishmaniasis 
in Government health institution in endemic areas. Balanced and adequate nutrition for 
those who have VL and malaria co-infected patients should be very mandatory in 
household level as well in health institutions who have patient admission wards.  
Health professionals in endemic areas should get appropriate training by the woreda 
health office/zonal health department and Medecins Sans Frontieres Holland project   
during VL-malaria patient examination and diagnosis. Immediate treatment of malaria and 
VL co-infected patients who have none palpable spleen should be in place.  
I. Zonal health department; should schedule training sessions in endemic areas for health 
professionals 
II. Woreda health office should arrange health care workers training, follow up, supportive 
supervision and provision of logistics. 
III. MSF-Holland should actively participate in the training process by budget allocation, arranging 
trainer, practical training on patients. 
IV. Health professional’s needs to be work as the updated of Ethiopian government VL and 
malaria guidelines, read and update the governments sustainable development goals to achieve 
as planned. 
V. Regional health Bureau and Federal Ministry of Health: should find solutions for the 
availability of VL drugs in all government hospitals. 
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9. ANNEXES 
Annex 1: Information sheet 
Research description: This is a study focusing on visceral leishmaniasis and malaria co-
infection associated mortality in Northwest Ethiopia.  
Name of Principal Investigator: Melkamu Amare 
Sponsor: Self 
Name of Organization: University of Gondar 
Purpose of the study: To assess co-infection of malaria and visceral leishmaniasis mortality 
associated factors. To suggest possible strategies to improve co-infected patients treatment 
improved treatment. 
Procedure: Institution based retrospective study was conducted after getting Ethical clearance 
from University of Gondar and permission from Medecins Sans Frontieres- Holland ethical review 
board. 
Risks: There were no foreseeable risks to the health institutions and on patients since the study 
only involves review of medical records.  
Benefits: There had no special benefits to the health institutions. However, the management of 
the health institutions will get the final report and be able to identify which areas they need to 
improve according to research information.  
Confidentiality: Confidentiality of information is guaranteed in that the information collected were 
accessible to the principal investigator and trained data collectors.  
Compensation: No compensation was available for any process of data collection but we are 
very grateful to the health institutions for taking part in this study.  
    Contact address: Principal investigator: Melkamu Amare, Mobile,+251918153653,  
Email: melkamuamre@yahoo. 
Advisors:  Name and position;  
1) Mr. Mekuriaw Alemayehu (Msc, PhD candidate) 
        Phone number: +25120510050      
        Email address: mekuriaw04@gmail.com 
2) Mr. KindieBantie (BSc, MPH) 
       Phone number: +251935478545   Email address:kkbantie@gmail.com 
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Annex 2: Assurance of the investigator 
I, the undersigned, MPH student declare that this thesis is my original work, except 
where otherwise acknowledged, this thesis has not been submitted for another degree 
award in this or any other university or institution. 
Name: ____________________ 
Signature: _________________ 
Date: _________________ 
Place of submission:  Institute of public health, College of medicine and Health 
Sciences, University of Gondar. 
Date of submission: ________________________________ 
This thesis work has been submitted for examination with our approval as university 
advisors.  
Advisors:  
  Name                                                                     Signature  
1. Mr. Mekuriaw Alemayehu (MSC, PhD candidate)            __________________ 
2. Mr. Kindie Bantie (BSC, MSC)              ___________________ 
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Annex 3. Data extraction sheet 
Assessment of factors associated with mortality among VL-malaria co-infected patients 
data extraction sheet at abdurafi MSF Holland Kala-azar, HIV/AIDS and malnutrition 
project (2010-2016). 
 
  Data extraction sheet, 2017 Code  Remark 
  Variables     
  Socio Demographic cxs     
1 Sex     
  Male     
  Female     
2 Age in years     
3 For how long lived in  current place in 
years 
    
  Residency status     
  Resident     
     Settler     
  Migrant worker      
4 Region of origin for migrant workers     
  Amhara     
  Tigray     
  Oromiya     
5 Benshangul     
  SNNP     
  Other     
  SIGNS AND SYMPTOMS     
  Duration of symptoms before admission 
in months 
    
  SIGNS AND SYMPTOMS after 
admission 
    
  Malaise     
  Yes     
3 No     
  Vomiting     
  Yes     
  No     
  Diarrhea     
  Yes     
4 No     
  Headache     
  Yes     
5 No     
  Edema     
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  Yes     
6 No     
  Joint pain     
  Yes     
7 No     
  Skin rash     
  Yes     
8 No     
  Fever      
  Anemia     Yes/no     
  Splenomegaly     
  Yes     
  No     
  if yes Spleen size (BCM) in cm     
  Hepatomegaly     
  Yes     
  No     
  Diagnostic laboratory tests for VL     
  RK39      
  positive     
  Negative     
  DAT test     
13 Negative     
  Borderline     
  Infection intensity in lymph node aspirate     
14 Infection intensity in Bone marrow 
aspirates 
    
15 Infection intensity in spleen aspirates     
16 Diagnostic laboratory tests for  Malaria     
  Blood film     
  Negative     
  PF     
  PV     
  PF + PV     
  Rapid diagnostic test(RDT)     
  Negative     
  PF     
17 PV     
  PF + PV     
  CBC profile at admission     
  WBC(number     
  RBC(Number)     
18 Platelate(number)     
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  Hemoglobin(number)     
  hematocrit(number)     
  CBC profile during discharge     
  WBC     
19 RBC     
  Platelet     
  Hemoglobin     
  hematocrit     
  Season of treatment     
  Autumn     
20 Spring     
  Summer     
  winter     
  Body mass index (BMI)  at admission     
  Body mass index (BMI)  during 
discharge 
    
  Degree of malnutrition     
  None     
  Mild     
  Moderate     
  Severe     
  Weight     
  weight in kg during admission     
  weight in kg during discharge     
  previous Medical treatment for VL     
  Yes     
  No     
  If yes When     
  year of treatment     
24 Treatment outcome     
  Cured     
  Default     
  Referred     
  Relapse     
  Type of Anti-leishmaniasis drugs     
  AmBisom only      
  Duration:                 
  AmBisom + Meltifosin     
  Duration:                 
  SSG only     
  Duration                            
  SSG + Paramomycin     
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  previous medical treatment outcome     
  cured     
  default     
  Referred     
  relapse     
  Previous anti-malarial treatment     
  Yes     
  No     
27 If yes When?     
  year of treatment     
  Type of anti malaria treatment     
  Artesunate + SP     
  Artemether     
28 Quinine     
  Artesunate     
  Artemether + lumefantrine     
  Treatment outcome     
  cured     
29 default     
  Transferred to other stracture     
  relapse     
  Type of Current treatment     
  Type of Anti-leishmaniasis drugs     
  AmBisom only      
30 Duration:                 
  AmBisom + Meltifosin     
  Duration:                
  SSG only     
  Duration                            
  SSG + Paramomycin     
  Current anti malarial treatment     
  Artemether     
  Quinine     
  Artesunate     
  Artemether + lumefantrine     
  Severity scoring     
33 prognosis     
  Very poor     
  poor     
                                                       good      
  Very good     
  Final treatment outcome for current 
treatment 
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  cured     
  Default     
34 Relapse     
  Transferred to other stracture     
  Dead     
  Concomitant diagnosis     
  Acute respiratory infection     
35 Yes     
  No     
  Ear,Nose and throat infection     
  Yes     
  No     
  Skin infections     
  Yes     
  No     
  Tuberculosis     
  Yes     
  No     
  If yes on treatment or treated     
  Yes     
  No     
                    If yes type of IP     
  Amoeba     
  Giardia     
  Strongloids     
  hookworm     
  Shistosomiasis     
  Yes     
  No     
  HIV/AIDS     
  Yes     
  No     
                              If yes on ART     
  Yes     
  No     
